DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes,

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes,

Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report

by Michael M. Messer, MD, and Irina V. Haller, PhD, MS Dr. Messer is with Behavioral Health Department, Essentia Health, Duluth, MN, and Dr. Haller is with Essentia Institute of

Risk Management Issues When Taking Locum Tenens Assignments

by Charles D. Cash, JD, LLM Mr. Cash is Assistant Vice President of Risk Management at PRMS, Inc., Arlington, Virginia. Innov Clin Neurosci. 2017;14(1–2)60–62. This ongoing column is dedicated to